In the News

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today released Part II of its white paper series, “Failure to Launch,” finding that anti-competitive rebating tactics by brand-name manufacturers, coupled with policy failures and inadequate incentives for biosimilar use, stifle biosimilars adoption in the United States.

Patent “thicketing” occurs when a brand-name pharmaceutical company accumulates dozens of patents near the end of the product lifecycle under the guise of “innovative” processes or development that warrant additional protections

We look forward to continuing to work with CMS to align coverage and payment policies to increase patient access to more affordable biosimilar and generic medicines.

We encourage the FDA to to build on its significant experience with insulin and foster efficient development of biosimilar insulins to lower costs and increase access for America’s diabetes patients.

The Association for Accessible Medicines (AAM) and its Biosimilars Council urged the FDA to reverse course on its current proposal for the naming of biological products, and rescind the suffix-based naming policy that acts as a barrier to biosimilars access for America’s patients.

The Association for Accessible Medicines (AAM) and its Biosimilars Council submitted comments in support of Pfizer’s Citizen Petition requesting the Food and Drug Administration (FDA) issue manufacturer guidance to ensure truthful and non-misleading communications concerning the safety and effectiveness of biosimilars